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 1. From historical background to current trends 
 Hippocrates first described malignant melanoma in the fifth century B.C., and the 
disease has been identified in Inca mummies in Peru. Laennec reported this neoplasm 
in the medical literature in 1806. During the following 150 years, the progress in the 
knowledge of the disease remained poor. This was mainly due to the lack of accurate 
diagnostic criteria. The past quarter of century has witnessed intense research activity 
directed towards understanding the biology of primary cutaneous melanoma beyond 
boundaries not previously imagined. Progress has been made in the recognition of 
melanoma tumorigenesis and host defense mechanisms which conteract it. Many in 
vitro and animal models, as well as clinico-pathologic correlations have brought new 
insights. Among the significant breakthroughs, several melanocyte-associated antigens 
and melanoma-specific antigens were identified and characterized in relation with the 
host immune response and melanoma regression. 
 Indeed, melanoma is one of the cancers with the largest number of identified 
typical antigens. It is also the malignant neoplasm with the highest rate of spontaneous 
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regression. Nevertheless, it remains the leading and ever growing cause of skin cancer 
deaths in the white population. It is one in the 12  most frequent cancers between the 
ages of 15 and 34 years. In addition, despite progress there is still an almost complete 
resistance of advanced stage of disease towards conventional non-surgical treatment 
modalities. This is reflected by the large interindividual variability in the evolution and 
outcome of the disease. 
 
 2. The 20-year celebration of the Mosan Study Group of Pigmented Tumors. 
 Two decades ago, the “ Groupe Mosan dʼEtude des Tumeurs Pigmentaires ” was 
founded in Liège. It was rooted in the combination of expertise in dermatopathology and 
clinical management. The aim of the Group was to bridge the gap whenever possible 
between basic science and practical clinical issues. Over the years, the Group has 
nurtured more than 50 publications, organized a dozen of international and local 
scientific meetings, and it actively participated in cooperative projects with the late W. 
Clark, A.B. Ackerman and the Instituto Regina Elena in Rome. The Group activity has 
always been rooted in a multi-pronged approach of cutaneous melanomas, and 
pioneered a series of diagnostic and prognostic methods. Its leitmotiv has always been : 
 “ Count whenever possible, 
 measure when you can, 
 if there is no measurement invent one, 
 if dermatopathology can help use it, 
 if bioengineering can help work on it. 
 In this context, with the help  
 or in spite of all ideas and all the technology, 
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 it all comes down 
 to shaping one individual at a time, 
 and to offer him or her the best chance to survive melanoma ”.  
 
 2.1. Epidemiology and prevention 
 Understanding epidemiology and combining it with proposals of adequate 
preventive measures is one of the goals of the Group. For more than 15 years, the 
Group clearly identified inconsistencies in the incidence of cutaneous melanomas and 
other skin cancers as reported by the Belgian National Cancer Registry. The surprising 
Belgian underregistration repeatedly identified by the Group was recently confirmed by 
colleagues in Gent.  
 Currently, the ratio between basal cell carcinomas (BCC) and squamous cell 
carcinomas (SCC) roughly equals 4 to 1. When combined, the incidence of BCC and 
SCC is about 10 times greater than that of cutaneous melanomas. The Group has 
shown a continuous trend in increase since 50 years in the ratios between cutaneous 
melanomas on the one hand, and BCC and SCC on the other hand. The incidence and 
mortality from cutaneous melanoma have indeed increased approximatively 5-10% per 
year. 
 Facing this alarming situation, yearly educational campaigns have been initiated 
by the Group among children attending primary schools of the Liège area. Indeed, 
intermittent or recreational ultraviolet light exposure during infancy undoubtedly plays a 
role in the development of melanoma. Prevention is therefore a realistic goal to curb the 
overall incidence and mortality rate of melanoma in young adults. 
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 2.2. Diagnosing early evolving cutaneous melanomas 
 Another concern of the Group was to develop new methods allowing accurate 
diagnosis of early evolving melanomas. Indeed, detecting and removing the neoplasm at 
its earliest stages provide the best chance to remain disease-free and to survive. 
 Cyanoacrylate skin surface stripping was introduced by our Group as a minimally-
invasive laboratory method for assessing the transepidermal migration of atypical 
melanocytes. The approach provides a superficial section of tissue parallel to the skin 
surface. Atypical melanocytes in the stratum corneum are highly specific for melanoma. 
They are not frequently seen on routine histopathologic sections that only scan a small 
fraction of the stratum corneum overlying the lesion. In contrast, they are found in the 
skin surface strippings in over 95% of melanomas. This non-invasive technique is rapid, 
easy to perform, and inexpensive. Its specificity and sensitivity are high enough to be 
considered by clinicians as an aid for diagnosing malignant melanomas. We recommend 
this ancillary technique as a screening procedure though not as a substitute for 
conservative excisional biopsy, when doubt persists in the diagnosis of atypical 
pigmented neoplasms.  
 More recently, we introduced a novel clinical appraoch consisting of examining 
lesional skin using a computer-assisted ultraviolet-emitting video camera. In addition, we 
advocate computerized image analysis of dermoscopic aspects as a promising 
diagnostic aid. 
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 2.3. Prospective insight in microscopic prognostic factors 
 The capability of a melanoma cell to give rise to metastasis is a complex property. 
Such a cell must at least be able to leave the primary neoplasm, to survive in the dermis 
in its way to a vessel, to cross the vascular wall, to survive in lymph or blood stream, to 
adhere somewhere to the vascular wall, and to retain the capability of proliferation. All 
these properties likely depend on different biological characteristics related to the 
malignant cell itself, but also to the host, through the immune system and other defense 
mechanisms. 
 There is strong evidence of the high prognostic value of the tumor thickness 
(Breslowʼs level) and presence of ulceration. However, it must be stressed that there are 
exceptions to that general rule. There exist reports stating that tumor thickness is not a 
good prognostic factor in thin melanomas. There are also thick melanomas apparently 
lacking competence for metastasis. Indeed, it is generally acknowledged that Clarkʼs 
level, growth phase, tumor infiltrating lymphocytes and regression have also prognostic 
value although consistency in the application in these attributes is not evident among 
pathologists. 
 Our Group studied particularly the value of kariometry and the biologic 
significance of the size of the neoplastic growth fraction, and its relationship with tumor 
thickness and vascularity. We introduced fractal and multifractal method analysis for 
better assessing angiogenesis. No correlation was found between proliferative markers 
(tritiated thymidine and Ki-67) and the nuclear size and cytologic aspects of melanoma 
cells. 
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 We have shown that, in general, the size of the neoplastic growth fraction was 
related to the thickness of the primary neoplasm. That means that during the infiltrative 
vertical growth phase there is a progressive enlarging proportion of proliferating cells 
leading to a higher probability for giving rise to a metastatic cell capable of proliferation 
rather than in a dormant stage. Indeed, most melanomas begin by a slow accretive 
indolent phase and they evolve progressively to an expanding proliferative and invading 
phase. The endophytic pattern is present when neoplastic cells are capable of readily 
invading the reticular dermis (Clarkʼs level IV). By contrast, when dermal invasiveness is 
impaired, the lesion exhibits an exophytic growth pattern (thick Clarkʼs level III). 
 The pattern of immunolabelling using a series of antibodies directed to 
melanoma-associated antigens was compared with the relapse-free interval and 
survival. The antigenic characteristics of the neoplastic cells seem to have no end in 
their variations, and none of them seems specific for metastatic capabilities. 
 We also compared the phenotypic presentation of the neoplasm with the 
distribution of tumor-infiltrating cells including lymphocytes (TIL), macrophages (TIM) 
and Factor XIIIa-positive dendrocytes (TID). A stochastic relationship was shown 
between the melanocyte-differentiation antigens immunoreactivities and the densities in 
TIL and TIM. An inverse relationship was present between TIL and TIM. No specific 
infiltrating pattern of TIL and TIM was found to predict metastases. We provided 
circumstantial evidence for a negative relationship between TID densities and the growth 
fraction of neoplastic cells in cutaneous melanomas. These TID represent an 
heterogeneous group of cells composed of mesenchymal cells, cancer-associated 
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macrophages and antigen-presenting cells. Factor XIIIa forms with other tissue 
transglutaminases, α2-macroglobulin and TNF-α a complex network of mediators 
influencing tumor progression in the skin. 
 A negative exponential correlation was also yielded between the peritumoral 
vascularity and the melanoma volume estimate. We found that the angiogenic 
phenotype of cutaneous melanomas occured as a stochastic event during neoplastic 
progression. Its expression was not mandatory for reaching high values in growth 
fraction. The absence of link between proliferation and vascularity might account for the 
unusual outcome of some cutaneous melanomas, including the dormant growth-stunted 
type and the metastasising thin melanomas. 
 
 2.4. Tumor thickness, a dramatic oversimplification in melanoma staging 
for therapeutic purpose ? 
 When examining cutaneous melanoma, the dermatopathologist aims to achieve, 
as simply and reliably as possible, a comprehensive diagnosis and prognosis with 
therapeutic relevance. Melanoma thickness must always be measured for staging 
purpose. However, it is a continuous variable for which there are no natural breakpoints, 
and there is a nonlinear relationship between tumor thickness and patient survival. With 
progression of the disease the number of metastatic lymph nodes becomes the 
strongest predictor of outcome. The presence of clinical or microscopic satellites around 
a primary melanoma is considered biologically equivalent to in-transit metastases. In the 
recent AJCC staging system, a microscopic satellite was defined as a nest of tumor cells 
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measuring 0.05 mm or greater that is present in the section in which the maximum 
thickness measurement has been made and is distinctly separate from the main tumor 
mass. Such a breackpoint in size might, however, appear biologically irrelevant. Indeed, 
it corresponds to the sensitivity of identifying neoplastic cell clusters using conventional 
microscopy. 
 The experience of the Group is similar to the current opinion expressed in the 
literature regarding melanoma invasion of the sentinel lymph node. Positive cases are 
only found when the primary melanoma is grossly thicker than 1 mm. However, our 
findings indicate that each of the stages I and II of the disease is biologically 
heterogeneous. Extravascular single cell micrometastases can be found in the 
peritumoral dermis in about 10% of cutaneous melanomas conventionally classified in 
stage I, and in almost 25% of those in stage II. These micrometastases are practically 
indistinguishable by conventional microscopy, but they are highlighted by a panel of 
antibodies directed to melanocyte-associated antigens (melan A-MART1, gp100-Pmel 
17 - HMB45, tyrosinase, NKI-C3). We contend that patients with local micrometastases 
without lymph node invasion might be more prone to develop the full-blown metastatic 
spread sometimes after a seemingly clinically silent phase that may extend well over 10 
years. 
 
 2.5. Melanocytic neoplasm boosted by ultraviolet light, recombinant human 
growth hormone and various cytokines 
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 Chronic ultraviolet light irradiation is responsible for melanocyte activation and 
mottled hyperpigmentation. Such alterations make skin prone to develop carcinomas 
and more rarely melanomas. We developed a non-invasive method to identify subjects 
at risk while this mottled hyperpigmentation is still “ invisible ” at the naked eye. 
Prevention could then be better targeted. 
 Computerized image analysis was used to compare lentigines (brown freckle-like 
cutaneous spots) induced by treatment with psoralens and ultraviolet light A (PUVA-
induced lentigines) with those induced by solar exposure (actinic lentigines). For these 
conditions, which appear to be distinctive clinically and histologically, the number, size 
and shape of the macules were analyzed, revealing significant differences in the two 
latter parameters. This indicates that UV irradiations of different wavelengths act 
differently on melanocytes and/or on the interrelation between melanocytes and 
keratinocytes. The overall effect is much more self-limited in PUVA lentigines than in 
actinic lentigines, suggesting that the pathophysiology of these lesions is probably 
different. We identified such problems in subjects who applied 5-methoxypsoralen-
containing sunscreens under the cover of a fallacious photochemoprotection claim. 
 The influence of insulin-like growth factor I on human melanocytes is increasingly 
recognized. Our Group reported for the first time the boosting effect of recombinant 
human growth  hormone on naevi. The triggered lesions had an increased growth rate, 
and showed histologic anisokaryosis, increased AgNOR and Ki-67 counts and abnormal 
patterns of melanocyte-associated antigens. Despite these changes, there was no clue 
for malignant transformation. 
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 2.6. Scrutinizing therapeutic promises 
 There is evidence that melanoma frequently elicits a strong host immune 
response. Partial regression of the primary neoplasm is the rule, particularly during the 
radial and accretive growth phase. The spontaneous regression of the primary 
melanoma either partial or complete does not preclude growth of metastases at 
distance. 
 Over the years, the Group assessed the benefits of immunotherapy alone or as 
an adjuvant to surgery. In the early days, the effects of topical immunotherapy using 
dinitrochlorobenzene (DNCB) were studied clinically and histologically. During the 15-
year period of this experimental immunotherapy, anecdotal cases of complete 
regression of primary and metastatic lesions were documented. In the global 
assessment, time-to-extracutaneous metastatic growth was delayed compared to 
dacarbazine treatment. The contention with regard  to DNCB and immunotherapy in 
general was “ do not kill the winning horse ”! It was, however, quite evident that 
cutaneous melanoma responded differently according its recognized stage of 
progression and other unknown factors.  
 More recently, interferon α (IFN-α) became available and is currently under 
investigation by our Group. Our working hypothesis explores the stage of neoplastic 
progression affecting the therapeutic outcome. It is indeed important to identify as 
closely as possible the numerous, complex and variable tumor rejection mechanisms. 
They reflect the antigenic diversity, and the variety of cellular and non-
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components involved in the elicitation and effector parts of the regression process. Time 
to first clinical metastasis appears to be a convenient parameter. During the stage II 
disease, stromal relationships appear to be crucial to hinder or promote the metastatic 
spread. IFN-α, even at low dosages, might affect some biologically important prognostic 
variables. Among them, any increase in neoplastic growth fraction, and presence of 
extravascular micrometastases and angiolymphatic invasion are likely key parameters. 
In stage II disease, the wisdom of integrating them beyond tumor thickness in the 
decision algorithm leading to the choice of adjuvant therapy is under investigation. New 
concepts on the horizon in the field of dermatopathology might show functional 
significance in the understanding of melanoma metastasis and in improving the 
therapeutic decision. 
 
 
 
 
